ArticleJournal of managed care & specialty pharmacy2022
Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Article in Journal of managed care & specialty pharmacy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Budget impact models for lung cancer interventions: A systematic literature review.Journal of managed care & specialty pharmacy · 2024Pooled it
- Myeloprotection effect of trilaciclib in lung cancer patients undergoing chemotherapy: a real-world retrospective study.Journal of thoracic disease · 2026Article
- [Incidence of severe cancer therapy-related thrombocytopenia and associated factors in children].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2026Observational
- Development and validation of a machine learning-based predictive model for chemotherapy-induced myelosuppression in colorectal cancer patients.Frontiers in medicine · 2026Article
- Cost-effectiveness analysis of trilaciclib for preventing myelosuppression in small cell lung cancer patients treated with etoposide, carboplatin, and atezolizumab.American journal of cancer research · 2025Article
- Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis.Acta pharmacologica Sinica · 2024Article
- Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.Advances in therapy · 2023Review
- Principles and Protocols For Post-Cryopreservation Quality Evaluation of Stem Cells in Novel Biomedicine.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.